Chemometec A/S
CSE:CHEMM

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
CSE:CHEMM
Watchlist
Price: 487.6 DKK -0.69% Market Closed
Market Cap: 8.5B DKK
Have any thoughts about
Chemometec A/S?
Write Note

Chemometec A/S
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chemometec A/S
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Chemometec A/S
CSE:CHEMM
Total Liabilities
kr111.4m
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
N/A
G
Gubra A/S
CSE:GUBRA
Total Liabilities
kr145.6m
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chemometec A/S
Glance View

Market Cap
8.5B DKK
Industry
Life Sciences Tools & Services

Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.

CHEMM Intrinsic Value
324.51 DKK
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Chemometec A/S's Total Liabilities?
Total Liabilities
111.4m DKK

Based on the financial report for Jun 30, 2024, Chemometec A/S's Total Liabilities amounts to 111.4m DKK.

What is Chemometec A/S's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
11%

Over the last year, the Total Liabilities growth was -11%. The average annual Total Liabilities growth rates for Chemometec A/S have been 12% over the past three years , 11% over the past five years .

Back to Top